{
  "id": 176479,
  "name": "ALNYLAM PHARMACEUTICALS",
  "slug": "alnylam-pharmaceuticals",
  "state": "MA",
  "description": "Biopharmaceutical company",
  "totalSpending": 1380000,
  "filings": 27,
  "yearlySpending": [
    {
      "year": 2018,
      "income": 60000
    },
    {
      "year": 2019,
      "income": 190000
    },
    {
      "year": 2020,
      "income": 150000
    },
    {
      "year": 2021,
      "income": 220000
    },
    {
      "year": 2022,
      "income": 220000
    },
    {
      "year": 2023,
      "income": 220000
    },
    {
      "year": 2024,
      "income": 240000
    },
    {
      "year": 2025,
      "income": 80000
    }
  ],
  "firms": [
    "THE MCMANUS GROUP"
  ],
  "lobbyists": [
    "JOHN MCMANUS",
    "BARRETT THORNHILL",
    "CHRISTINA HOCHUL",
    "ALANNA TEMME",
    "LAWREN GEER"
  ],
  "issues": [
    "MMM",
    "HCR",
    null
  ],
  "sampleDescriptions": [
    "Reimbursement and access to novel therapeutics based on RNA interference and related administration costs.",
    "Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340.",
    "Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892 - Bipartisan Budget Act of 2018.",
    "Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. H.R. 2113, Prescription Drug STAR Act of 2019. S. 551, the REFUND Act of 2019.",
    "Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 2543, the Prescription Drug Pricing Reduction Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019.",
    "Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. H.R. 3, the Lower Drug Costs Now Act of 2019, and H.R. 19, the Lower Costs, More Cures Act of 2019.",
    "CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget Act of 2018. S. 551, the REFUND Act of 2019. S. 3129/H.R. 19, the Lower Costs, More Cures Act. Home administration of injectable and infusible drugs including CMS-1744-IFC and CMS-5531-IFC.",
    "CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Public Law 115-123.",
    "CY 2021 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, CMS-1730-P RIN 0938-AU-06. Implementation of Public Law 115-123. Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Most Favored Nation (MFN) Model, (CMS-5528-IFC).",
    "Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P). Provisions related to vial wastage rebates in Part B. Implementation of Home Infusion Therapy Benefit.",
    "Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN). \n\nProvisions related to vial wastage rebates in Medicare Part B including in Sec. 102 of S. 2164/H.R. 19 - Lower Costs, More Cures Act of 2021.",
    "Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN). \n\nProvisions related to vial wastage rebates in Medicare Part B including in Sec. 102 of S. 2164/H.R. 19 - Lower Costs, More Cures Act of 2021 and Sec. 90004 of H.R. 3684 - Infrastructure Investment and Jobs Act.\n\nProvisions included in Subtitle J - Drug Pricing of H.R. 5376 - Build Back Better Act.",
    "Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN). \n\nProvisions included in Subtitle J of H.R. 5376 - Build Back Better Act.",
    "Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN). Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act. Issues related to access and coverage in Medicare Part D program.",
    "Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN). Provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill. Issues related to access and coverage in Medicare Part D program.",
    "Inclusion of study on genetically targeted technologies in S. 4348 - FDASLA Act of 2022 and H.R. 7667 - Food and Drug Amendments of 2022.",
    "Implementation of Home Infusion Therapy Benefit in Medicare CY 2021 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Policy Issues and Healthcare Common Procedure Coding System (HCPCS) Level II Proposed Rule (CMS-1738-P) and Durable Medical Equipment Fee Schedule Adjustments To Resume the Transitional 50/50 Blended Rates to Provide Relief in Rural Areas and Non-Contiguous Areas; Extension of Timeline for Final Rule Publication (CMS-1687-RCN). Provisions included in Title I - Subtitle B of PL.117-169/H.R. 5376 - Inflation Reduction Act of 2022. Issues related to access and coverage in Medicare program.",
    "Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 H.R. 5539, S.3131 - ORPHAN Cures Act Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act",
    "Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Provisions related to home infusion in H.R.8816 - American Medical Innovation and Investment Act of 2024 (Rep. Buchanan) Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act",
    "Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Provisions related to home infusion in H.R.8816 - American Medical Innovation and Investment Act of 2024 (Rep. Buchanan), and H.R. 7623 - Telehealth Modernization Act of 2024 Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022 Issues related to access and coverage in Medicare program. Support for H.R.5547/S.476 - Maintaining Investments in New Innovation Act"
  ],
  "years": [
    2018,
    2019,
    2020,
    2021,
    2022,
    2023,
    2024,
    2025
  ],
  "growthRate": 33,
  "trajectory": "growing",
  "yearsActive": 8,
  "avgAnnualSpending": 172500,
  "peakYear": 2024,
  "lobbyistCount": 5,
  "firmCount": 1,
  "issueCount": 2,
  "industry": "healthcare"
}